Clofarabine

Cat. No.:	HY-A0005		
CAS No.:	123318-82-2	1	
Molecular Formula:	C ₁₀ H ₁₁ ClFN	₅ 0 ₃	
Molecular Weight:	303.68		
Target:	Nucleoside Antimetabolite/Analog; Autophagy; Apoptosis		
Pathway:	Cell Cycle/DNA Damage; Autophagy; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months


SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	3.2929 mL	16.4647 mL	32.9294 mL	
		5 mM	0.6586 mL	3.2929 mL	6.5859 mL	
		10 mM	0.3293 mL	1.6465 mL	3.2929 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
vo		one by one: 10% DMSO >> 40% PEC ng/mL (6.85 mM); Clear solution	6300 >> 5% Tween-8	0 >> 45% saline		
	2. Add each solvent	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.85 mM); Clear solution				
		ng/mL (6.85 mM); Clear solution				

BIOLOGICAL ACTIVITY		
Description	Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC ₅₀ =65 nM) by binding to the allosteric site on the regulatory subunit ^[1] .	
In Vitro	Clofarabine potently inhibits DNA synthesis. Clofarabine demonstrates strong in vitro growth inhibition and cytotoxic activity (IC ₅₀ values=0.028-0.29 μM) in a wide variety of leukaemia and solid tumour cell lines ^[1] . ?Clofarabine (0.01-0.1 μM) inhibits proliferation of NB4 cells, which may be related with the down-regulation of Bcl-2 and	

Product Data Sheet





induction of apoptosis^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	NB4 cells
Concentration:	0.01-0.1 μM
Incubation Time:	48 hours
Result:	Inhibited proliferation of NB4 cells in a concentration-depended manner.

Apoptosis Analysis^[2]

Cell Line:	NB4 cells
Concentration:	0.01-0.1 μΜ
Incubation Time:	24 hours
Result:	Apoptosis rate increased obviously.

Western Blot Analysis^[2]

Cell Line:	NB4 cells
Concentration:	0.01-0.1 μM
Incubation Time:	24 hours
Result:	Bcl-2 expression decreased obviously.

In Vivo

Clofarabine (330 mg/kg, after a 7-day treatment) causes the death of mice. Higher mortality rates were observed in daytime treatment groups, while more animals survived in night treatment groups. Significant differences of LD_{50} are found at various time points especially at 12:00 noon and 12:00 midnight^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Kunming mice (18-22 g, with equal numbers of male and female mice) $^{[3]}$
Dosage:	600, 480, 384, 307, 246 mg/kg
Administration:	Injected intraperitoneally at 8:00 am, 12:00 noon, 8:00 pm and 12:00 midnight; 7 days continuous administration
Result:	LD ₅₀ s of 8:00 am, 12:00 noon, 8:00 pm, 12:00 midnight were 333.59, 319.73, 362.58 and 366.92 mg/kg, respectively.

CUSTOMER VALIDATION

- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
- Oncotarget. 2020 Nov 3;11(44):3921-3932.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Peter L Bonate, et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):855-63.

[2]. Hai-Bo Liu, et al. [Effect of clofarabine on proliferation and Bcl-2 expression of NB4 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):571-3.

[3]. Jia-Jie Luan, et al. Dosing-time contributes to chronotoxicity of clofarabine in mice via means other than pharmacokinetics. Kaohsiung J Med Sci. 2016 May;32(5):227-34.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA